Tempest Therapeutics Inc (TPST)

$3.42 +0.15 (4.59%)
Market Cap 13.43M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 246,500
Avg Vol 118,378
Day's Range N/A - N/A
Shares Out 4.44M
Stochastic %K 34%
Beta -2.43
Analysts Sell
Price Target $9.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
GJ_Rockabilt
GJ_Rockabilt Dec. 5 at 12:18 AM
$TPST I think CEO Brady needs to take a look at MTS due diligence and refuse to pay.
0 · Reply
Simpson8935
Simpson8935 Dec. 4 at 11:23 PM
$TPST Here are my thoughts after seeing the PRE14A: Summary: Why only 1 out of 14 (Factor) remained After digging through the documents, the situation is crystal clear. Party A (presumed to be Roche) had the chance but passed: They conducted thorough due diligence in May and June but ultimately said "No" in July. There were no competing bids: After Party A walked away, no one else offered a proposal as concrete or capable of saving the company as Factor did. So, it had to be Factor: They wanted to sell 1120 at a premium (Plan A), but with no buyers, they shook hands with Factor as a condition to keep the company alive (Plan B). However, the termination fee being set at a very low $300K shows that Brady never abandoned the lingering hope (or strategy) until the very end: "If Party A changes their mind, we are ready to take them back at any time." My eyes are strictly on the news before the Dec 31st meeting. After that, I'm just waiting to see the truth: will Factor be a savior or a hyena?
4 · Reply
joeyknowie
joeyknowie Dec. 4 at 10:58 PM
$TPST for deal to make sense 35 percent post deal must equal better than 100 percent pre deal.
0 · Reply
joeyknowie
joeyknowie Dec. 4 at 10:43 PM
$TPST I totally understand that it has been a point of major debate — and I admit it’s unclear — but nothing has yet convinced me that the separation agreements of the former executives were altered to extend their option exercise date. So I’m looking to see if Form 4’s are filed tomorrow.
1 · Reply
claybridge
claybridge Dec. 4 at 9:53 PM
$TPST wouldn't be surprised to see this close over $4 tomorrow. Technicals have been repairing over the past two trading sessions and RSI is trending up. Hang in there friends, this is a bumpy ride.
1 · Reply
ManiacalSlug
ManiacalSlug Dec. 4 at 9:37 PM
$TPST Multiple filings after market close tomorrow?
1 · Reply
deson
deson Dec. 4 at 9:35 PM
$TPST Who is expecting news before December 31? Notice of Annual Meeting of stockholders Meeting and the topic with No. 7. : "To conduct any other business properly brought before the meeting."
4 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 4 at 9:12 PM
$NVS , $TPST : I'm looking for a Novartis ( $NVS ) turnkey Strategic Alliance, Drug Buyout or Merger with Tempest Therapeutics ( $TPST ). Liver Cancer, CAR-T.
0 · Reply
lousjamsession
lousjamsession Dec. 4 at 8:56 PM
$TPST
1 · Reply
hzain
hzain Dec. 4 at 8:44 PM
$TPST
1 · Reply
Latest News on TPST
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 26, 2025, 4:05 PM EST - 8 days ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 8:00 AM EST - 9 days ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nov 19, 2025, 9:00 AM EST - 15 days ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:30 AM EST - 4 weeks ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 4 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 5 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 6 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 6 months ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 7 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 7 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 8 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 8 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 9 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 9 months ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 10 months ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 10 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 11 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 9:06 AM EDT - 1 year ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 1 year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Oct 10, 2023, 4:05 PM EDT - 2 years ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Tempest to Present at the Jefferies Global Healthcare Conference

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Apr 27, 2023, 4:58 PM EDT - 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

GJ_Rockabilt
GJ_Rockabilt Dec. 5 at 12:18 AM
$TPST I think CEO Brady needs to take a look at MTS due diligence and refuse to pay.
0 · Reply
Simpson8935
Simpson8935 Dec. 4 at 11:23 PM
$TPST Here are my thoughts after seeing the PRE14A: Summary: Why only 1 out of 14 (Factor) remained After digging through the documents, the situation is crystal clear. Party A (presumed to be Roche) had the chance but passed: They conducted thorough due diligence in May and June but ultimately said "No" in July. There were no competing bids: After Party A walked away, no one else offered a proposal as concrete or capable of saving the company as Factor did. So, it had to be Factor: They wanted to sell 1120 at a premium (Plan A), but with no buyers, they shook hands with Factor as a condition to keep the company alive (Plan B). However, the termination fee being set at a very low $300K shows that Brady never abandoned the lingering hope (or strategy) until the very end: "If Party A changes their mind, we are ready to take them back at any time." My eyes are strictly on the news before the Dec 31st meeting. After that, I'm just waiting to see the truth: will Factor be a savior or a hyena?
4 · Reply
joeyknowie
joeyknowie Dec. 4 at 10:58 PM
$TPST for deal to make sense 35 percent post deal must equal better than 100 percent pre deal.
0 · Reply
joeyknowie
joeyknowie Dec. 4 at 10:43 PM
$TPST I totally understand that it has been a point of major debate — and I admit it’s unclear — but nothing has yet convinced me that the separation agreements of the former executives were altered to extend their option exercise date. So I’m looking to see if Form 4’s are filed tomorrow.
1 · Reply
claybridge
claybridge Dec. 4 at 9:53 PM
$TPST wouldn't be surprised to see this close over $4 tomorrow. Technicals have been repairing over the past two trading sessions and RSI is trending up. Hang in there friends, this is a bumpy ride.
1 · Reply
ManiacalSlug
ManiacalSlug Dec. 4 at 9:37 PM
$TPST Multiple filings after market close tomorrow?
1 · Reply
deson
deson Dec. 4 at 9:35 PM
$TPST Who is expecting news before December 31? Notice of Annual Meeting of stockholders Meeting and the topic with No. 7. : "To conduct any other business properly brought before the meeting."
4 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 4 at 9:12 PM
$NVS , $TPST : I'm looking for a Novartis ( $NVS ) turnkey Strategic Alliance, Drug Buyout or Merger with Tempest Therapeutics ( $TPST ). Liver Cancer, CAR-T.
0 · Reply
lousjamsession
lousjamsession Dec. 4 at 8:56 PM
$TPST
1 · Reply
hzain
hzain Dec. 4 at 8:44 PM
$TPST
1 · Reply
Onedaytolive
Onedaytolive Dec. 4 at 8:43 PM
$TPST Why did Brady choose a reverse takeover with Factor out of the 14 companies that signed NDAs through MTS? After examining various back-end factors, we found that the current market for CAR-T-based rrMM is around $1 billion. Furthermore, Phase 1 of TPST-2003, conducted in certain regions, has been completed, with data expected to be released in 2026. In other words, Brady could have sold TPST for around $100 million if they wanted to, yet they chose Factor's acquisition. This suggests Brady may have selected the reverse takeover from multiple options while having some understanding of the partial Phase 1 results for TPST-2003. The referenced image was found on X, but the characteristics of TPST-1120 and 1495 appear highly compatible with Angel Doctor's CAR-T program.
2 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Dec. 4 at 8:35 PM
$TPST Nice volume Something is brewing no doubt in my mind
0 · Reply
josegodoy
josegodoy Dec. 4 at 7:52 PM
$TPST don’t know any of the specifics but…. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/
2 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 4 at 7:25 PM
$TPST The Dilutions are already reflected in today's Stock Price. No Double Jeopardy, if you please.
1 · Reply
claybridge
claybridge Dec. 4 at 7:14 PM
$TPST the remaining $750K will be interesting. Personally, I'd like to see Brady purchase the remaining offering. That would go a LONG way of bolstering investor's confidence. Besides, a soon to be CoB should own a ton of shares, not the measly # Brady currently owns.
1 · Reply
lousjamsession
lousjamsession Dec. 4 at 5:41 PM
$TPST
1 · Reply
lgb2
lgb2 Dec. 4 at 5:25 PM
$TPST what happened to the cockroach buyout they saw I was a scam fraud garbage nothing
0 · Reply
brxzx
brxzx Dec. 4 at 3:42 PM
$TPST
1 · Reply
lousjamsession
lousjamsession Dec. 4 at 3:10 PM
$TPST
0 · Reply
brxzx
brxzx Dec. 4 at 2:39 PM
$TPST 4 soon 💪🏻🔋
0 · Reply
sanabu
sanabu Dec. 4 at 1:58 PM
$TPST dead
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 4 at 1:13 PM
$TPST Bought more at $3.33.
0 · Reply